These are the stories of the British coronavirus that you need to know today.
Infectious disease “flat”
COVID-19 infections in the United Kingdom may have leveled off. National Bureau of Statistics (ONS) Infection survey data suggests.
Between November 8 and 14, ONS estimated that 664,700 people in the United Kingdom were infected with COVID-19, which is about one in 80 people.
The highest infection rates are in junior high school, teens and older, and young adults.
There are 7.14 new infections per 10,000 people per day, which represents about 38,900 new cases per day.
In Scotland, infection rates increased throughout most of October, but now appear to be flat. In the last week, 33,800 people have been infected with COVID-19, which is equivalent to 1 in 155 people.
In Wales, infection rates peaked around the end of October, declining in the last two weeks, and in the last week, 18,400 people in Wales have been infected with COVID-19, one in 165, according to ONS. Corresponds to.
In Northern Ireland, prices peaked around mid-October. In the last week, 13,600 people were infected with COVID-19, equivalent to 1 in 135 people.
Katherine Kent of ONS commented: “There are early signs that the national level of infectious diseases in England may have leveled off, but this hides many fluctuations at the regional level.”
Growth rates range from 0% to + 2%.
According to the University of Oxford, people who have recovered from COVID-19 are unlikely to be re-infected with COVID-19 for at least 6 months after the initial infection. Preprint A study of front-line healthcare professionals in the UK.
The study was conducted between April and November, and 89 of the 11,052 non-antibody staff developed a new symptomatic infection. None of the 1246 staff with antibodies developed symptomatic infections.
Professor David Eyre, the leader of the collaborative research, said:
“No new symptomatological infections were found in any of the participants who tested positive for the antibody.”
The authors conclude that “further research is needed to determine the correlation between long-term duration and post-infection immunity.”
The most infectious person in the first week
Patients with COVID-19 have the highest levels of virus in the first 5 days and show no evidence of live virus in the body 9 days after the onset of symptoms, a systematic review led by the University of St Andrews Lancet Microorganisms Found.
Lead author Dr. Muge Cevik said in a news release: “This is the first systematic review and meta-analysis that comprehensively investigated and compared the viral load and release of these three human coronaviruses.
“It clearly explains why SARS-CoV-2 spreads more efficiently than SARS-CoV-1 and MERS-CoV and is so difficult to contain. People are within the first 5 days of infection. Most likely to infect the corona virus. Symptoms.
“Our findings are consistent with contact tracing studies that suggest that most viral infection events occur very early, especially within the first 5 days after the onset of symptoms, and symptoms begin. It shows the importance of self-isolation immediately after the virus. “
Free NHS influenza Vaccination is done Expansion From December 1st to 50-64 years old. This means that your doctor may still be vaccinated against the flu when you start vaccination against the coronavirus.
The Ministry of Health said: “The deployment of influenza vaccines to people in their 50s and above is separate from the future deployment of COVID-19 vaccines, and people can be vaccinated against influenza and COVID-19 in parallel. NHS We have the facilities to manage both. “
Professor Martin Landley, co-principal investigator for the Oxford Recovery Trial, responded to the WHO Guideline Development Group, which advises COVID-19 not to use remdesivir. BMJ.
“Trials reported so far have not shown the effect of remdesivir on survival. People discuss the need for early use, but with little benefit (for example, one person). (Improved survival) Fifth, people with mild illness have a lower risk, so the absolute number of lives saved will be less. This must be given by intravenous infusion for 5-10 days, course Also keep in mind that it is a drug that costs about £ 2000 per, so remdesivir is not cheap, convenient, and does not affect the mortality rate of the most at-risk people. “
BMA welcomed updates Visa extension For international doctors following lobbying by the health union.
Dr. Chaand Nagpaul, Chairman of the Council, said: “Our international colleagues have been working tirelessly during the pandemic.
“We are very grateful to this important group of staff and they shouldn’t have had to worry about their immigration status.”
Meanwhile, NHS workers appear to be set up to avoid public sector wage freezes reported in the UK.
Health Minister Matt Hancock did not speculate on the Prime Minister’s spending review plan, Told the BBC He “always fights for the NHS.”
Scotland’s highest level 4 limit will come into force in 11 council areas tonight.
At a press conference, Prime Minister Nicola Sturgeon admitted that she was “totally cursed and fed up” with the new restrictions.
Two weeks with stricter restrictions Announcement From Friday, November 27th to Northern Ireland. Meetings other than the support bubble are prohibited.
We data It shows that 50% of adults in the UK had enough information about the government’s plans to manage a pandemic under the national blockade. This is compared to 34% of Tier 3 two weeks ago, 37% of Tier 2 and 45% of Tier 1.
ONS’s Tim Vizard commented: You’re getting along with others and have less physical contact outside the home. We also found that fewer people said they were affected by the pandemic than they were two weeks ago. “
Arthritis medicine Baricitinib An international study led by scientists at Imperial College London and the Karolinska Institute in Sweden has the potential to improve the survival rate of COVID-19 in older patients. Univadis From Medscape report.
In this study, patients admitted to multiple hospitals in Italy and Spain had a 71% reduced risk of death compared to those who did not take the drug. The study also found that 17% of patients who received the drug died or needed to be ventilated, compared to 35% in the control group.
Professor Justin Stepping, co-author of Imperial, commented: “This is one of the first COVID-19 treatments to move from a computer to a clinic or laboratory. It can work against this virus.
“This study suggests that the drug may help patients with moderate to severe COVID-19 recover and provide a new weapon against the virus. Further investigation of the drug’s potential. Large-scale clinical trials are currently underway for. How. “
US FDA approved Baricitinib combination therapy with remdesivir for COVID-19.
University of Birmingham Preprint study Describes laboratory experiments that suggest that polysaccharide polymer nasal sprays may be effective in providing protection against the SARS-CoV-2 virus for up to 48 hours.
Sprays are made from products that are already used in foods and medicines.
The lead author, Dr. Richard Moke’s, said:
“But what this spray does is add a second layer of protection to prevent and delay viral infections.”
See more Medscape Global Coronavirus Updates Coronavirus Resource Center.